[HTML][HTML] Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis

ME Wechsler, P Akuthota, D Jayne… - … England Journal of …, 2017 - Mass Medical Soc
Background Eosinophilic granulomatosis with polyangiitis is an eosinophilic vasculitis.
Mepolizumab, an anti–interleukin-5 monoclonal antibody, reduces blood eosinophil counts and …

Use of fractional exhaled nitric oxide to guide the treatment of asthma: an official American Thoracic Society clinical practice guideline

…, A Barochia, I Soghier, P Akuthota… - American journal of …, 2021 - atsjournals.org
Background: The fractional exhaled nitric oxide (FE NO ) test is a point-of-care test that is used
in the assessment of asthma. Objective: To provide evidence-based clinical guidance on …

Eosinophil knockout humans: uncovering the role of eosinophils through eosinophil-directed biological therapies

…, AJ Bredenoord, ID Pavord, P Akuthota… - Annual review of …, 2021 - annualreviews.org
The enigmatic eosinophil has emerged as an exciting component of the immune system,
involved in a plethora of homeostatic and inflammatory responses. Substantial progress has …

Defining a severe asthma super-responder: findings from a Delphi process

…, P Wark, P Bardin, PK Fu, P Akuthota… - The Journal of Allergy …, 2021 - Elsevier
Background Clinicians are increasingly recognizing severe asthma patients in whom biologics
and other add-on therapies lead to dramatic improvement. Currently, there is no agreed-…

Eosinophilic pneumonias

P Akuthota, PF Weller - Clinical microbiology reviews, 2012 - Am Soc Microbiol
This review starts with discussions of several infectious causes of eosinophilic pneumonia,
which are almost exclusively parasitic in nature. Pulmonary infections due specifically to …

[HTML][HTML] Eosinophils and eosinophilic immune dysfunction in health and disease

DJ Jackson, P Akuthota… - European Respiratory …, 2022 - Eur Respiratory Soc
The functions ascribed to eosinophils have classically been limited to host defence against
certain parasitic infections and potentially deleterious effects in the setting of specific …

[HTML][HTML] Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis

…, J Brown, S Mallett, SW Yancey, P Akuthota… - Journal of Allergy and …, 2019 - Elsevier
Background In a recent phase III trial (NCT02020889 ) 53% of mepolizumab-treated versus
19% of placebo-treated patients with eosinophilic granulomatosis with polyangiitis (EGPA) …

Eosinophils as antigen-presenting cells in allergic upper airway disease

P Akuthota, H Wang, PF Weller - Current opinion in allergy and …, 2010 - journals.lww.com
Akuthota, LA Spencer, A. Radke, PF Weller, unpublished data). Lipid raft disruption has
been shown to impair APC function in other professional APCs [33,34] . … 2• Akuthota P, Wang …

Trends in mortality from idiopathic pulmonary fibrosis in the European Union: an observational study of the WHO mortality database from 2001–2013

…, JD Salciccioli, BS Shea, P Akuthota - European Respiratory …, 2018 - Eur Respiratory Soc
Idiopathic pulmonary fibrosis (IPF) is the most common of the idiopathic interstitial
pneumonias and is characterised by progressive accumulation of scar tissue in the lungs. The …

Eosinophilic asthma

…, A Bush, J Stokes, P Nair, P Akuthota - The Journal of Allergy and …, 2020 - Elsevier
Asthma endotypes are constantly evolving. Currently, there are no universally accepted
criteria to define endotypes. The T H 2-high endotype can have either allergic or nonallergic …